The Efficacy and Safety of Irinotecan, Paclitaxel and Oxaliplatin (IPO) Regimen as Salvage in Relapsed/Refractory Ovarian Germ Cell Tumors

被引：0
|
作者：
Sivasree Kesana
Perumal Kalaiyarasi Jayachandran
Gangothri Selvarajan
Subramaniam Murali Carthikeyan
Venkatraman Radhakrishnan
Tenali Gnana Sagar
Trivadi Sundaram Ganesan
机构：
[1] Cancer Institute (W.I.A),Department of Medical Oncology
[2] Cancer Institute (WIA),Department of Medical Oncology
来源：
Indian Journal of Gynecologic Oncology | 2023年 / 21卷
关键词：
Ovarian GCT; Relapsed/Refractory ovarian germ cell tumor; Salvage chemotherapy; Irinotecan; Paclitaxel and Oxaliplatin (IPO); Cisplatin ineligible Ovarian GCT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Gemcitabine, Oxaliplatin and Paclitaxel (GemPOx ) in Patients with Relapsed or Refractory Germ Cell Tumors After High Dose Chemotherapy, A Retrospective Single-Center Experience
    Acar, Ramazan
    Erturk, Ismail
    Kiziloz, Halil
    Okcelik, Sezgin
    Yildiz, Birol
    Aykan, Musa Baris
    Keskin, Gul Sema Yildiran
    Buyukturan, Galip
    Akin, Serkan
    Karadurmus, Nuri
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2020, 30 (04): : 191 - 196
  • [32] Implementing Indiana regimen salvage high-dose chemotherapy in relapsed germ cell tumors in Slovakia.
    Chovanec, Michal
    Rusinakova, Zuzana
    Ladicka, Miriam
    Obertova, Jana
    Palacka, Patrik
    Rejlekova, Katarina
    Sycova-Mila, Zuzana
    Orszaghova, Zuzana
    Lesko, Peter
    Mardiak, Jozef
    Vranovsky, Andrej
    Mego, Michal
    Drgona, Lubos
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [33] Paclitaxel, ifosfamide, and cisplatin (TIP) salvage therapy for patients (pts) with relapsed testicular germ cell tumors (GCT).
    Mardiak, J
    Salek, T
    Sycova-Mila, Z
    Hlavata, Z
    Obertova, J
    Mego, M
    Reckova, M
    Koza, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 414S - 414S
  • [34] FEASIBILITY AND EFFICACY OF DHAOX REGIMEN AS SALVAGE AND MOBILIZING THERAPY IN RELAPSED /REFRACTORY LYMPHOMAS
    Coviello, E.
    Giannoni, L.
    Pastori, G.
    Mitscheunig, L.
    Avenoso, D.
    Minetto, P.
    Guolo, F.
    Miglino, M.
    Clavio, M.
    Lemoli, R. M.
    Marco, G.
    Ballerini, F.
    HAEMATOLOGICA, 2016, 101 : 399 - 400
  • [35] Determination of efficacy of TIP combination (paclitaxel, ifosfamide, cisplatin) as first salvage therapy for patients with relapsed germ cell tumors in a poor prognosis group
    Mardiak, J.
    Rejlekova, K.
    Mego, M.
    Rajec, J.
    Sycova-Mila, Z.
    Obertova, J.
    Salek, T.
    Reckova, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Salvage treatment of relapsed or refractory germ-cell tumours Reply
    Wessalowski, Ruediger
    Schneider, Dominik T.
    Goebel, Ulrich
    Calaminus, Gabriele
    LANCET ONCOLOGY, 2013, 14 (12): : E486 - E487
  • [37] Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer
    McKenzie, Hayley S.
    Mead, Graham
    Huddart, Robert
    White, Jeff D.
    Rustin, Gordon J. S.
    Hennig, Ivo M.
    Cozens, Kelly
    Cross, Nadia
    Bowers, Megan
    Wheater, Matthew J.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 458 - +
  • [38] Efficacy and Safety of Gemcitabine/Paclitaxel/Oxaliplatin Combination Regimen (GemPOx) on Recurrent Germinoma
    Noguchi, Mayuko
    Yamasaki, Kai
    Azuma, Sakiko
    Kikuchi, Natsumi
    Tanimura, Kazuki
    Hira, Kouta
    Nitani, Chika
    Okada, Keiko
    Fujisaki, Hiroyuki
    Hara, Junichi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [39] A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
    Nabil Adra
    David J. Vaughn
    Lawrence H. Einhorn
    Nasser H. Hanna
    Samuel A. Funt
    Matt Rosales
    Ahsan Arozullah
    Darren R. Feldman
    Investigational New Drugs, 2022, 40 : 1087 - 1094
  • [40] A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
    Adra, Nabil
    Vaughn, David J.
    Einhorn, Lawrence H.
    Hanna, Nasser H.
    Funt, Samuel A.
    Rosales, Matt
    Arozullah, Ahsan
    Feldman, Darren R.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1087 - 1094
12345